The prostate gland Incidence of Prostate Cancer and

  • Slides: 22
Download presentation

The prostate gland

The prostate gland

Incidence of Prostate Cancer and Prostate Cancer Deaths, Based on Annual Predictions

Incidence of Prostate Cancer and Prostate Cancer Deaths, Based on Annual Predictions

Risk Factors Associated with Prostate Cancer • Probable risk factors - Age - Race

Risk Factors Associated with Prostate Cancer • Probable risk factors - Age - Race - Genetic • Possible risk factors - Environmental - Occupational - Diet - Hormonal

Clinical Presentation

Clinical Presentation

DIAGNOSIS • • Digital rectal examination (DRE) Prostate specific antigen (PSA) Transrectal ultrasonography (TRUS)

DIAGNOSIS • • Digital rectal examination (DRE) Prostate specific antigen (PSA) Transrectal ultrasonography (TRUS) Prostate biopsy

Digital rectal examination (DRE)

Digital rectal examination (DRE)

Serum PSA in Untreated Patients with Prostatic Cancer Stage A 1 A 2 B

Serum PSA in Untreated Patients with Prostatic Cancer Stage A 1 A 2 B 1 B 2 C D 1 D 2 Mean (ng/ml) 5. 1 7. 96 5. 64 14. 25 32. 46 51. 46 410. 00 Percentage above normal 45 69 75 78 75 93 97

Prostate specific antigen (PSA) • คาปกตของ serum PSA - 4 ng/m. L (Hybritech) -

Prostate specific antigen (PSA) • คาปกตของ serum PSA - 4 ng/m. L (Hybritech) - 2. 8 ng/m. L (Yang Pros-check) • ������ BPH ������ Prostate Cancer ������� biopsy ����� simple prostatectomy �����

PSA Age-Spacific reference range Age (year) PSA (ng/ml) 40 -49 50 -59 60 -69

PSA Age-Spacific reference range Age (year) PSA (ng/ml) 40 -49 50 -59 60 -69 70 -79 2. 5 3. 5 4. 5 6. 5

Treatment • Watchful waiting • Surgery and Radiation therapy • Hormonal therapy - Luteinizing

Treatment • Watchful waiting • Surgery and Radiation therapy • Hormonal therapy - Luteinizing Hormone-Releasing Hormone Agonists - Antiandrogens - Combined Hormonal Blockade • Chemotherapy

Hormone Therapy

Hormone Therapy

Antiandrogens

Antiandrogens

EVALUATION OF THERAPEUTIC OUTCOMES • tumor size, involved lymph nodes, and tumor markers such

EVALUATION OF THERAPEUTIC OUTCOMES • tumor size, involved lymph nodes, and tumor markers such as PSA • PSA level is checked every 6 months for the first 5 years

Thank for attentions

Thank for attentions